Ethnomedicinal Plants with Protective Effects against Beta-Amyloid Peptide (Aβ)1-42 Indicate Therapeutic Potential in a New In Vivo Model of Alzheimer's Disease.
Alzheimer’s disease
G. pallida
amyloid-beta peptide
antioxidant response
chemosensing
ethnomedicine
oxidative stress
phytotherapy
survival
Journal
Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981
Informations de publication
Date de publication:
21 Sep 2022
21 Sep 2022
Historique:
received:
04
07
2022
revised:
08
09
2022
accepted:
17
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with unmet medical need. This investigation consisted of testing a range of ethanolic ethnomedicinal plant extracts (n = 18) traditionally used in the treatment of disorders such as anxiety, delirium, and memory loss. They were then screened for in vitro inhibitory activity against acetylcholinesterase (AChE), butylcholinesterase (BuChE), beta-secretase 1/beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1), and antioxidant activities. Plants with potent activities were further characterised using a recently developed in vivo model of AD, Globodera pallida. The ability of phytoextracts to protect this organism against amyloid-beta Aβ (1-42) exposure was assessed by measuring chemosensing, survival rate, production of reactive oxygen species (ROS), and antioxidant responses. Extracts (n = 5) from Juglans regia (leaves), Ellettaria cardamomum (seeds), Cinnamomum zeylanicum (bark), Salvia officinalis (leaves/flowers), and Hypericum perforatum (flowers) exerted concentration-dependent inhibitory activities against AChE and BuChE. Three of these plant extracts (i.e., J. regia, E. cardamomum, and S. officinalis) possessed strong concentration-dependent inhibitory activity against BACE1. Furthermore, the five selected medicinal plant extracts not only enhanced significantly (p < 0.05) the nematode’s chemosensing, survival rate, and antioxidant responses (i.e., anti-ROS production, mitochondrial reductase activity, oxidized glutathione (GSSG) to reduced glutathione (GSH) ratio), but also greatly restored (p < 0.05) in a concentration-dependent manner the Aβ (1-42)-induced deleterious changes in these same parameters. In brief, this investigation highlights plant extracts with strong anti-AD activities which could be trialled as novel therapeutic supplements or undergo further biodiscovery research.
Identifiants
pubmed: 36290588
pii: antiox11101865
doi: 10.3390/antiox11101865
pmc: PMC9598277
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Alzheimer's Research UK
ID : ARUK-NC2019-NI
Organisme : Medical Research Council
ID : CIC-CD1718-CIC25
Pays : United Kingdom
Organisme : Invest Northern Ireland
ID : RD101427 11-01-17-008
Références
J Biol Chem. 2010 Apr 23;285(17):12463-8
pubmed: 20212036
Neural Plast. 2016;2016:8501693
pubmed: 26881137
Curr Neuropharmacol. 2013 Jul;11(4):414-29
pubmed: 24381531
Curr Alzheimer Res. 2004 Aug;1(3):183-8
pubmed: 15975066
Neurochem Res. 2011 Nov;36(11):2096-103
pubmed: 21706234
Br J Pharmacol. 2012 Sep;167(2):324-52
pubmed: 22646481
Mini Rev Med Chem. 2017;17(1):33-43
pubmed: 26791737
Int J Prev Med. 2013 Apr;4(Suppl 1):S31-5
pubmed: 23717766
Food Res Int. 2017 May;95:117-124
pubmed: 28395819
Cells. 2021 Sep 19;10(9):
pubmed: 34572130
Biol Res. 2009;42(1):93-8
pubmed: 19621136
J Nat Prod. 2004 Dec;67(12):2141-53
pubmed: 15620274
Ann Pharm Fr. 2015 Jul;73(4):281-8
pubmed: 25934446
Molecules. 2016 Jul 02;21(7):
pubmed: 27384550
Transl Neurodegener. 2013 Feb 28;2(1):6
pubmed: 23445907
Phytomedicine. 2016 Sep 15;23(10):1005-11
pubmed: 27444345
J Neurosci Res. 2004 Mar 15;75(6):742-50
pubmed: 14994335
FEBS J. 2012 Apr;279(7):1291-305
pubmed: 22325686
P T. 2010 Apr;35(4):208-11
pubmed: 20498822
Drugs R D. 2017 Mar;17(1):53-64
pubmed: 27888449
Curr Med Chem. 2013;20(8):976-83
pubmed: 23210783
Int J Prev Med. 2017 Feb 07;8:5
pubmed: 28250905
Int J Food Sci Nutr. 2011 Dec;62(8):781-6
pubmed: 21627404
Eur J Med Chem. 2017 Apr 21;130:379-392
pubmed: 28279845
BMC Complement Altern Med. 2014 Jan 14;14:23
pubmed: 24422705
Biofactors. 2007;31(3-4):219-27
pubmed: 18997285
Molecules. 2014 Jan 09;19(1):767-82
pubmed: 24413832
Phytother Res. 2004 Apr;18(4):315-24
pubmed: 15162368
Biochem Pharmacol. 1961 Jul;7:88-95
pubmed: 13726518
Acta Pharm. 2010 Mar;60(1):119-28
pubmed: 20228046
Eur J Pharmacol. 2013 Mar 15;704(1-3):70-7
pubmed: 23461850
Neural Regen Res. 2023 Jan;18(1):113-114
pubmed: 35799520
Neurotoxicology. 2012 Oct;33(5):1314-21
pubmed: 22935099
Mol Med Rep. 2014 Aug;10(2):689-94
pubmed: 24859152
Biochim Biophys Acta. 2014 Aug;1842(8):1240-7
pubmed: 24189435
Phytother Res. 2006 Jun;20(6):427-37
pubmed: 16619340
Int J Clin Exp Med. 2009 Oct 05;2(3):254-65
pubmed: 19918318
Pharmacology. 2003 Oct;69(2):59-67
pubmed: 12928578
Neurochem Res. 2015 Jun;40(6):1283-93
pubmed: 25944473
Eur J Med Chem. 2014 Mar 21;75:21-30
pubmed: 24508831
Molecules. 2016 Dec 22;22(1):
pubmed: 28025519
Biomed Pharmacother. 2017 Mar;87:489-495
pubmed: 28073098
Curr Pharm Des. 2006;12(35):4613-23
pubmed: 17168769
Pharmacol Biochem Behav. 2003 Jun;75(3):669-74
pubmed: 12895685
Nutr Neurosci. 2017 Feb;20(2):103-109
pubmed: 25153536
PLoS One. 2010 Feb 22;5(2):e9339
pubmed: 20179756
Front Pharmacol. 2015 Sep 30;6:221
pubmed: 26483691
Front Mol Neurosci. 2011 Sep 14;4:19
pubmed: 21949501
Biotechnol Adv. 2017 Mar - Apr;35(2):178-216
pubmed: 28043897
ScientificWorldJournal. 2013 Oct 24;2013:917082
pubmed: 24363627
J Clin Pharm Ther. 2003 Feb;28(1):53-9
pubmed: 12605619
Curr Genomics. 2007 Dec;8(8):550-8
pubmed: 19415128
PLoS One. 2011 Jan 28;6(1):e16564
pubmed: 21305046
Br J Nutr. 2009 Apr;101(8):1140-4
pubmed: 18778529
J Pharmacol Exp Ther. 2006 Jun;317(3):1143-9
pubmed: 16495207
Phytother Res. 2003 Jan;17(1):1-18
pubmed: 12557240